DNA Testing Global Market Report 2024

The DNA testing market size has grown rapidly in recent years. It will grow from $16.04 billion in 2023 to $17.9 billion in 2024 at a compound annual growth rate (CAGR) of 11.6%. The expansion witnessed in the historical period can be attributed to several factors, including the increasing prevalence of chronic diseases, growing demand for precision medicine, the rise of direct-to-consumer (DTC) testing, increasing interest in population genomics, expanding forensic investigations, and the demand for genetic screening.

The DNA testing market size is expected to see rapid growth in the next few years. It will grow to $28.07 billion in 2028 at a compound annual growth rate (CAGR) of 11.9%. The anticipated growth in the forecast period is driven by rising incidences of genetic diseases, the growing utilization of DNA diagnostics, the expansion of healthcare infrastructure, increasing awareness of disease prevention, heightened investment by manufacturers, and greater adoption of companion diagnostics. Key trends expected in the forecast period include the utilization of next-generation sequencing (NGS) and polymerase chain reaction (PCR), the integration of preimplantation genetic diagnosis (PGD) into assisted reproductive technologies (ART), the miniaturization of testing devices, the introduction of new DNA testing products, and the development of novel assays, biomarkers, diagnostic tools, point-of-care testing, and non-invasive prenatal testing (NIPT).

The rising incidence of genetic disorders is anticipated to drive the growth of the DNA testing market in the foreseeable future. Genetic disorders result from abnormalities in an individual's DNA, leading to physical or developmental anomalies. Factors contributing to the increasing prevalence of genetic disorders include heightened awareness, advancements in diagnostic techniques, expanded genetic screening, and a growing prevalence of consanguineous marriages in certain populations. DNA testing plays an increasingly vital role in diagnosing, prognosticating, and making treatment decisions for individuals with genetic disorders, facilitating personalized medical interventions and family planning strategies based on an individual's genetic profile. For example, as per the World Health Organization (WHO) in February 2023, congenital diseases account for an estimated 240,000 infant deaths worldwide within 28 days of birth annually. Additionally, according to the Centers for Disease Control and Prevention (CDC), approximately 6,000 babies are born with Down syndrome in the United States each year, equating to around 1 in every 700 births. Thus, the escalating prevalence of genetic disorders is propelling the DNA testing market forward.

Key players in the DNA testing market are concentrating on developing advanced testing solutions such as precancer detection DNA tests to enhance early cancer diagnosis and treatment. Precancer detection DNA tests are diagnostic assays designed to detect genetic alterations or biomarkers associated with the early stages of cancer development. For instance, in November 2023, Lucid Diagnostics Inc., a US-based company specializing in esophageal cancer prevention diagnostics, introduced EsoGuard 2.0, the next-generation EsoGuard Esophageal DNA Test. This advanced DNA test employs molecular techniques and enhanced sample DNA yields to improve assay performance and reduce costs. The test involves collecting esophageal cell DNA using the EsoCheck Cell Collection Device, followed by bisulfite conversion, polymerase chain reaction (PCR) amplification, and next-generation sequencing to identify methylation at specific gene sites linked to esophageal precancer and cancer. Providing results indicating the presence or absence of epigenetic changes consistent with esophageal precancer and cancer, this DNA test is pivotal in cancer prevention and early detection efforts.

In February 2021, Thermo Fisher Scientific Inc., a US-based biotechnology company, acquired Mesa Biotech for $450 million. This acquisition aims to bolster Thermo Fisher Scientific's position in the expanding point-of-care molecular diagnostics market, particularly for infectious diseases, by harnessing Mesa's innovative technology platform. Mesa Biotech Inc. is a US-based biotechnology company specializing in the research and development of DNA and RNA molecular testing technology.

Major companies operating in the DNA testing market are F. Hoffmann-La Roche Ltd., Thermo Fisher Scientific Inc., Abbott Laboratories, Danaher Corporation, Siemens Healthineers GmbH, Becton, Dickinson and Company, GE HealthCare Technologies Inc., Laboratory Corporation of America Holdings (LabCorp), Quest Diagnostics Incorporated, Eurofins Scientific SE, Agilent Technologies, Illumina Inc., PerkinElmer Inc., bioMérieux SA, Beckman Coulter Inc., Bio-Rad Laboratories Inc., QIAGEN N.V., Natera Inc, Myriad Genetics Inc., BGI Genomics Co. Ltd., Cepheid, NeoGenomics Laboratories Inc, Ancestry.com LLC, 23andMe Holding Co, Ambry Genetics Corporation, MyHeritage Ltd, Biocartis SA, CENTOGENE N.V., Everlywell Inc, Atlas Biomed Group Limited, Veritas Genetics.

North America was the largest region in the DNA testing market in 2023. The regions covered in the DNA testing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the DNA testing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

DNA testing involves analyzing an individual's DNA, which contains the instructions for an organism's development, functioning, and traits. This process includes extracting DNA from cells, often obtained from bodily fluids or tissues such as blood, saliva, or hair, and then examining specific regions or sequences of the DNA molecule.

The primary product types in DNA testing include equipment, consumables, software, and services. Equipment comprises various instruments, devices, and tools utilized in the analysis of DNA samples. Various technologies are employed in DNA testing, including polymerase chain reaction (PCR)-based methods, in-situ hybridization, microarray analysis, and next-generation sequencing (NGS) for DNA diagnosis. These techniques find applications across various fields such as newborn DNA screening, prenatal DNA carrier screening, oncology diagnostics, histopathology, pre-implantation diagnosis, infectious disease diagnostics, pharmacogenomics diagnostic testing, identity verification, forensics, and more.

The DNA testing market research report is one of a series of new reports that provides DNA testing market statistics, including DNA testing industry global market size, regional shares, competitors with a DNA testing market share, detailed DNA testing market segments, market trends and opportunities, and any further data you may need to thrive in the DNA testing industry. This DNA testing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The DNA testing market consists of revenues earned by entities by providing services such as paternity testing, maternity testing, genetic health risk assessment, carrier screening, pharmacogenomics testing, forensic DNA analysis, and nutrigenomics testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The DNA testing market also includes sales of sterile swabs, DNA collection kits, thermal cyclers, DNA sequencers, microarray platforms, DNA extraction kits, polymerase chain reaction (PCR) reagents, and microscopes. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.